[Next-Generation Sequencing Book]

Featured prior sponsors:

Regeneron
St. Jude
Illumina BioSpace
Georgetown University
Northeastern University
Become a sponsor

News

Lastest news items (10)

Submit Archive Subscribe
  • [Photo] J.W. Bizzaro • December 14, 2025
    Rare diseases sometimes open windows into everyday biology that we otherwise miss. Take Sedaghatian-type spondylometaphyseal dysplasia (SSMD) as an example. It's a condition so rare it affects only a handful of families worldwide. Tragically, most affected infants die soon after birth, but a few linger long enough to show something striking: their brains deteriorate at breakneck speed in a pattern that echoes severe dementia in the elderly. The entire process traces back to one defective gene: GPX4.

    Source: https://scitechdaily.com/a-tiny-enzyme-flaw-may-explain-how-dementia-begins/

    GPX4 codes for the enzyme glutathione peroxidase 4, which is embedded in neuronal membranes. Its job is to disarm lipid peroxides before they can harm the cell. When the enzyme fails, either because of an inherited mutation or because levels drop over a lifetime, those peroxides multiply unchecked. Membranes essentially oxidize in a runaway chain reaction. The result is ferroptosis: iron-driven cell death where the neuron balloons, bursts, and spills damaging contents that inflame nearby cells. Apoptosis, by comparison, looks tidy – this is messy and can spread.

    Findings like these push us to reconsider Alzheimer's disease itself. For years the field has argued over which protein misfolds first, amyloid-beta plaques or tau tangles, and which one truly drives the damage. Yet the terminal event that kills the neuron may not depend on either. Emerging evidence suggests that ferroptosis could represent a common endpoint, potentially contributing to neurodegeneration. Different insults can start the trouble, but they often finish by wrecking membranes the same way.

    If we interrupt ferroptosis, the cell holds together no matter what sparked the crisis. Work in laboratory animals using agents such as the iron-binding drug deferoxamine or the experimental compound J147 shows this clearly. Neurons stop dying explosively, regain metabolic stability, kick autophagy back into gear, and begin clearing junk while rebuilding connections. Preserving the neuron becomes the priority; tracing the exact upstream culprit matters less once the cell survives.

    RELEVANT DRUGS AND TRIALS

    The "Synthetic Shields" (Geroneuroprotectors):
    • J147 (Curcumin derivative):
      • Mechanism: Targets mitochondrial ATP synthase to reduce oxidative stress (ROS) and boosts BDNF to repair synapses.
      • Status: Has completed FDA Phase 1 (safety) trials in humans; Phase 2 efficacy trials for Alzheimer's are the next step.
    • CMS121 (Fisetin derivative):
      • Mechanism: Inhibits fatty acid synthase (FASN) to alter cell membrane composition, making lipids resistant to peroxidation.
      • Status: In active clinical development (Phase 1 safety profile established); moving toward efficacy testing.
    The Iron Chelators (The "Sledgehammers"):
    • Deferoxamine (Desferal):
      • Mechanism: Physically removes excess iron to stop the reaction that triggers ferroptosis.
      • Trial History: The 1991 Crapper McLachlan study (intramuscular injections) showed a 50% reduction in cognitive decline.
      • Status: Since deferoxamine can no longer be patented, complex delivery methods are being actively investigated.
    • Deferiprone:
      • Mechanism: An oral iron chelator that crosses the blood-brain barrier more easily than deferoxamine.
      • Status: Deferiprone was tested in the "3D Study", which ran from 2018 to 2023. The study authors and subsequent editorial commentaries concluded that the drug failed not because it didn't work, but because it caused "Functional Iron Deficiency" within the neurons.
  • [Photo] Editor • December 10, 2025
    The US Defense Advanced Research Projects Agency (DARPA) has launched Generative Optogenetics (GO), a program that aims to let living cells write their own DNA and RNA on demand using beams of light. Instead of synthesizing genetic material in distant factories and then inserting it, scientists plan to engineer microbes and human cells to assemble precise nucleic-acid sequences inside the body whenever specific wavelengths strike them. DARPA's Biological Technologies Office describes the effort as a shift from today's slow, lab-bound gene synthesis to rapid, programmable biology that operates directly within organisms. Program manager Matthew Pava leads the initiative, which remains in early exploratory stages with no public milestones yet announced.

    Source: https://www.darpa.mil/research/programs/go
    YouTube video: https://www.youtube.com/watch?v=RtpZhZcbQXQ
  • [Photo] Editor • November 29, 2025
    A new fluorescence-based sensor now lets researchers watch DNA repair unfold in real time inside living cells. When both strands of the DNA helix snap – a lethal lesion if left unrepaired – the sensor signals the arrival of the MRN complex (MRE11, RAD50, and NBS1 proteins) within seconds. High-resolution movies reveal MRN rapidly resecting the broken ends, generating single-stranded DNA overhangs up to 1,000 nucleotides long in under ten minutes to prepare the site for homologous recombination. Tracking hundreds of individual breaks showed striking variation: some sites resect smoothly and complete repair, while others stall at intermediate steps, hinting that local chromatin environment or break complexity governs outcome. Published in Nature Communications, the work provides the first direct view of this key genome-maintenance process in action.

    ARTICLE

    da Silva RC, Eleftheriou K, Recchia DC, et al. Engineered chromatin readers track damaged chromatin dynamics in live cells and animals. Nat Commun. 2025;16(1):10127. https://doi.org/10.1038/s41467-025-65706-y

    Via: https://scitechdaily.com/this-new-sensor-shows-dna-repair-in-real-time-video/
  • [Photo] Linna Green • November 11, 2025
    December 12th, 2025 10:00 EST
    https://www.bocsci.com/delivery-nanocarriers-to-desirable-vascular-destinations-fortuitous-tropism-vs-cognizant-targeting.html
    Free registration

    In this session, Dr. Vladimir Muzykantov will present an in-depth analysis of the current advances and challenges in drug targeting, biomaterials, nanomedicine, drug delivery systems (DDS), intracellular delivery, and biotherapeutics (Bios).

    HIGHLIGHTS

    Biotherapeutics (Bios) as a new pharmacological class: Discussion of their catalytic precision, biological potency, and delivery challenges within systemic circulation.

    Delivery challenges and bottlenecks: Exploration of nanoscale targeting requirements, intracellular addressing (cytosol vs nucleus), and barriers to effective biodistribution and clearance.

    Cognizant vs. Fortuitous Targeting Approaches: Comparison of rational ligand-based targeting versus chance discoveries ("fortuitous homing"), including advantages, limitations, and potential synergies.

    Mechanistic understanding through DDS design: How tracing, modeling, and controlled modification of nanocarriers advance rational design for vascular delivery.

    Re-engineering Fortuitous Nanocarriers: Strategies to transform serendipitous findings into predictable and tunable delivery platforms through modulation of carrier configuration, size, shape, and biological context.

    Translational impact – Vascular Nanomedicine: Case studies where endothelial-targeted antioxidants, antithrombotics, and anti-inflammatory agents outperform untargeted drugs in animal models of lung injury, ischemia-reperfusion, and sepsis.
  • [Photo] J.W. Bizzaro • November 9, 2025
    James Dewey Watson (April 6, 1928 – November 6, 2025) was best known for the discovery that changed biology forever: the double-helix structure of DNA.

    In 1953, working with Francis Crick and drawing on essential data from Rosalind Franklin and others, he showed how DNA is organized – a paired spiral whose sequence of bases carries the instructions for life. That discovery did more than answer a question; it created the foundation for entirely new fields of science.

    Watson also played a central role in the next major transformation: integrating computer science with biology. When he became director of the Human Genome Project from 1990 to 1992, sequencing the complete human genome was widely considered impossible within a single lifetime. Watson argued for rapid, large-scale sequencing, immediate public release of all data, and global collaboration. Those decisions shaped the way genomic data are handled today and made modern bioinformatics possible.

    He was an early and strong supporter of personalized medicine – the idea that knowledge of a person's full genome could guide medical care. In 2007-2008, at the age of 79-80, he became one of the first people in the world to have their entire genome sequenced and published, demonstrating his confidence in the future of genomic medicine.

    Watson spent his career pushing biology toward a future in which genomic information is collected and then analyzed and applied using computers. Today's laboratories, filled with machines that process billions of DNA bases, owe as much to his vision as they do to the double helix he helped reveal. He did not simply discover the structure of DNA; he ensured that we would keep reading and using it.
  • [Photo] Editor • October 30, 2025
    Researchers cultured 250+ gut bacteria and found 134 "hidden" phages that could be awakened. Most stayed silent in the lab until exposed to human gut cells or complex bacterial communities.

    That means phage activity depends on both the microbiome and the human host. Some phages have even lost the genes needed to reactivate, becoming permanent passengers.

    This study gives us a powerful resource of real, testable phage-host pairs and shows that phages are active players shaping our gut ecosystem.

    ARTICLE

    Dahlman, Samuel, Tom O. Delmont, Alejandro Reyes, Anna L. Mallott, and Emily B. Hollister, et al. "Isolation, Engineering and Ecology of Temperate Phages from the Human Gut." Nature 638 (2025): 145-152. https://doi.org/10.1038/s41586-025-09614-7.
  • [Photo] Editor • October 27, 2025
    A large UK study of breast cancer patients has found that sequencing the entire genome of a tumor can reveal important information about the aggressiveness of the disease and which treatments are most likely to work. By linking whole-genome data from thousands of tumors to long-term survival records, researchers identified specific DNA changes tied to prognosis and uncovered therapeutic targets that standard tests routinely miss, potentially allowing doctors to someday choose more effective, personalized therapies while sparing patients from treatments that offer little benefit.

    ARTICLE

    Turnbull, Clare, Helen Davies, Peter Van Loo, Serena Nik-Zainal, and colleagues. "Clinical Potential of Whole-Genome Data Linked to Mortality Statistics in Patients with Breast Cancer in the UK: A Retrospective Analysis." The Lancet Oncology (2025). https://doi.org/10.1016/S1470-2045(25)00400-0
  • [Photo] Editor • October 23, 2025
    Researchers have created a new biological-age clock called gtAge that predicts aging more accurately than most existing methods. It works by analyzing two features measurable in a regular blood sample – the sugar patterns attached to antibodies (IgG glycosylation) and gene-activity levels in white blood cells. The team used deep reinforcement learning, an advanced form of artificial intelligence, to combine these data. They hope gtAge may eventually help doctors check whether a patient's diet, medication, or lifestyle changes are genuinely slowing aging and cutting the risk of age-related diseases.

    ARTICLE

    Xia, Yao, Syed Mohammed Shamsul Islam, Xingang Li, Abdul Baten, Xuerui Tan, and Wei Wang. "Deep Reinforcement Learning – Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome." Engineering (2025). https://doi.org/10.1016/j.eng.2025.08.016.
  • [Photo] Editor • October 17, 2025
    A team of researchers has built a new tool called MetaGraph, designed to let scientists search across some of the largest collections of DNA and RNA sequences ever assembled (databases that together hold more than a quadrillion bases). With MetaGraph, queries that once took weeks, or were simply impossible, can now return results in minutes, even when the search spans global repositories such as the Sequence Read Archive. This speed and reach now make it possible to detect subtle relationships between particular genes, microbial species, and human diseases that were previously hidden inside vast amounts of raw, unanalyzed sequencing data.

    ARTICLE

    Karasikov, Mikhail, Harun Mustafa, Daniel Danciu, Oleksandr Kulkov, Marc Zimmermann, Christopher Barber, Gunnar Rätsch, and André Kahles. "Efficient and Accurate Search in Petabase-Scale Sequence Repositories." Nature (October 8, 2025). https://doi.org/10.1038/s41586-025-09603-w.
Submit Archive Subscribe

© 1998-2025 Scilico, LLC. All rights reserved.